Introduction
The human and mouse p16
INK4a genes exhibit unusual properties in the sense that they encode two transcripts derived from the two alternative ®rst exons 1a and 1b and they encode two structurally unrelated proteins (Duro et al., 1995; Mao et al., 1995; Stone et al., 1995; Quelle et al., 1995) . The a transcript codes for the p16 INK4a /MTS1/CDKN2 protein that blocks the G 1 to S transition of the cell cycle by speci®cally inhibiting cyclin D1-3-dependent CDK4/6 and the resulting phosphorylation of the pRb protein (for a review, see Sherr, 1996) . The b transcript encodes a p19 ARF protein of 132aa in man and 156aa in mouse, of which the primary structure is totally unrelated to that of p16 INK4a (Larsen, 1996) . Strikingly, in spite of this unrelated structure, p19
ARF also arrests cells in G 1 /S and G 2 /M by a presently unknown mechanism Liggett et al., 1996) .
Because of its location on human chromosome band 9p21 that is frequently rearranged on both alleles in a variety of solid tumors and acute lymphoblastic leukemias (Olopade et al., 1992; Coleman et al., 1994, and references herein), p16 INK4a is considered as a tumor suppressor gene whose inactivation plays a major role in the genesis and/or development of tumors. In this respect, the most representative example comes from studies on familial melanomas in which point mutations in the p16
INK4a gene have been shown to co-segregate with the occurrence of tumors in patients (for a review, see Flores et al., 1996) . Consistently, it has been abundantly documented that these mutations are directly responsible for the incapacity of the mutated p16
INK4a protein to bind CDK4/6 and the concomitant loss of its inhibitory function (Koh et al., 1995; Wick et al., 1995; . Altogether, these data strongly point to p16
INK4a as the genuine target of alterations that impair the p16 locus. In contrast, the place of p19 ARF in tumorigenic processes is still poorly understood. While expression of a wild type copy of human p19 ARF in cells devoid of functional Rb protein was shown to arrest cells in G 1 (Liggett et al., 1996) , a recent report by Sherr's group has shown that point mutations located in the part of exon 2 that is common to p16
INK4a and p19 ARF did not result in the incapacity of the latter to exert its inhibitory role (Quelle et al., 1997) . In addition, the same group also showed that the aminoterminal part of p19 ARF encoded by exon 1b is necessary and sucient to abolish the functional activity of the protein. To date, with only one published exception, no mutation in exon 1b has been so far detected in several tumor types (Fitzgerald et al., 1996) . For these reasons, p19
ARF is not likely to be signi®cantly involved in tumorigenic processes, at least as regards a number of dierent tumor types.
In ARF in these cells indicated that the protein is not expressed in some cell lines in which the b transcript is abundant. The signi®cance of this result is discussed with regard to the tumorigenic process.
Results
Preparation and validation of antibodies to the human hp19 ARF protein
A rabbit antiserum (referred to as serum 73) raised against a recombinant GST-hp19 ARF was prepared (see Materials and methods). This serum immunoprecipitated a 35 S-methionine-labeled protein with a mobility slightly lower than that of the p16
INK4a protein after in vitro transcription and translation of the b and the a transcripts, respectively ( Figure 1a and data not shown). This band was not detected by nonimmune rabbit serum and was eliminated upon addition of an excess of ARF in the immunoprecipitation reaction mixture. In addition, the serum did not recognize the in vitro p16 INK4a product (data not shown).
Next, the anti-hp19 ARF serum was utilized to immunoprecipitate the protein from extracts of metabolically labeled HeLa cells (the choice of HeLa cells was dictated by the report that the b transcript is expressed in this cell line, see Mao et al., 1995) . A protein was readily detected by immunoprecipitation in total cell extracts (Figure 1b, lane 3) , but not in extracts of Reh cells chosen as negative control (lane 1), since the p16 locus is homozygously deleted in this cell line (Duro et al., unpublished data, Zhou et al., 1995) . The intensity of the band greatly diminished upon mixing of the serum with GST-hp19 ARF (lane 4). The same band was also present in cell extracts from Meg-01 human tumor cells with a megakaryoblastic origin (lane 5). Consistent with these data, the protein was also detected by Western blot in immune complexes of HeLa cell and Meg-01 cell extracts but not in those of Reh cells (see Figure 3) . In separate experiments with metabolically labeled HeLa cells, the signals obtained by ECL revelation and by autoradiography were superimposable (data not shown).
Taken together, these data indicate that serum 73 has the ability to speci®cally detect the human p19 ARF protein.
Indirect immuno¯uorescence studies
Serum 73 was also used to perform indirect immunouorescence (IIF) on cells grown on glass coverslips. In the case of HeLa cells, a micropunctuated staining with anti-hp19 ARF antibody was observed in the nucleus (Figure 2 ). Nucleoli were generally not stained. On the other hand, the staining was homogeneous in all cells examined, suggesting that the protein levels do not grossly¯uctuate during the cell cycle.
Depending on the nature of the cells, a more or less intense nuclear staining was observed. For example HS-27 human ®broblasts which were karyotypically and morphologically normal exhibited a much lower uorescence than HeLa cells analysed simultaneously. Nevertheless, the intensity of the staining appeared to be homogeneous in all the nuclei examined, again suggesting that the protein levels did not vary very much throughout the cell cycle. This behaviour did appear not to be entirely consistent with RNA data on human peripheral lymphocytes that indicated a dramatic increase of the b transcript level upon stimulation by phytohemagglutinin plus IL-2 (Stone et al., 1995) . This result suggests a parallel¯uctuation of the protein level. The fact that HeLa cell immuno¯uorescence patterns did not reveal any protein level¯uctuations may be related to dierent Finally, Western blotting of immune complexes con®rmed that in normal ®broblasts, hp19
ARF was expressed at low levels (Table 1 ; see also Figure 5 ).
Characterization of hp19 ARF in various cells
Hemopoietic cells of dierent sources (cell lines or fresh cells) were analysed by immunoprecipitation followed by Western blot for their p16
INK4a and hp19 ARF contents. A set of these analyses is presented in Figure 3 and summarized in Table 1 . While some cells (HeLa, Meg-01, Nalm-6) displayed signi®cant levels of the protein, or only low levels (K562), others were totally negative (Reh, Raji, Daudi, HL-60, Jurkat), although the reasons for this negative expression were dierent. Reh cells have a homozygous deletion of the p16 locus (Duro et al., unpublished data and Zhou et al., 1995) . But some of the other cell lines, particularly those with a mature B-type phenotype (Raji, RPMI 8226, Daudi) were veri®ed by Southern blot analysis to bear the whole p16 locus. Strikingly, these latter cells exhibited abundant levels of the b transcript which were readily detected by Northern blot analysis (see Table 1 ). These results that were reproduced in independent experiments and by dierent procedures (IP, IP/WB, immmuno¯uorescence) made it impossible to correlate positively the expression of RNA and protein.
Since p16 INK4a and hp19 ARF are encoded by the same gene, the p16
INK4a protein expression in the dierent cell lines was also examined (Figure 3 ). In general, our results were in agreement with those already published INK4a promoter has been shown to be hypermethylated, thus resulting in total absence of expression (Duro et al. 1996) . To our knowledge, no methylation of the 1b promoter has been reported so far (see also Swaord et al., 1997) .
Transient transfection experiments
In an attempt to get insight into one mechanism responsible for the absence of the hp19 ARF , the translation capacity of the b transcript cDNA isolated from one hp19 ARF protein negative cell line, Raji, was tested. By using transcription/translation in vitro assay, the cDNA appeared to generate a product that was immunoprecipitated by serum 73 and that migrated at the expected position for hp19 ARF (data not shown).
The ability of b cDNAs to encode the hp19 Indirect immuno¯uorescence analysis of HeLa cells recovered 48 h after transfection generated a nuclear pattern (Figure 4b ). Similar patterns were observed with anti-HA antibodies. By taking into account the mean of several experiments, 10 ± 15% of the cells appeared to be positively stained. Because of the high intensity of the positively transfected cells, the micropunctuated staining pattern was not obvious. It also diered from the pattern displayed by murine NIH3T3 cells infected with p19 ARF , which mainly consisted of speckles (Quelle et al., 1997) .
The hp19
ARF protein exhibits a moderate stability
HeLa cells were labeled for 6 h with [
35 S]-methionine+cysteine, then submitted to chase for 19 h in normal medium, the analysis of the hp19 ARF content from identical numbers of cells indicated that some signi®cant labeling of the protein was still present at the 8th hour of chase but not at the 19th hour ( Figure  5a ). These data are consistent with a moderate stability of the protein exceeding at least 8 h in proliferating HeLa cells. However, it cannot be excluded that the cell line status of HeLa cells introduces a bias as it has been recently mentioned that p19
ARF levels tend to accumulate in cell strains passaged in culture (Quelle et al., 1997) . Accordingly, the relative stability of p19 ARF (as well as that of p16 INK4a ) may rely on the particular status of tumoral cells inde®nitely maintained in culture. In experiments performed with the normal human ®broblast HS-27 cell line, we noticed that the growth rate of these cells decreased during the time they were studied, suggesting that they were evolving toward senescence. Consistent with this possibility, the morphology of the cells became¯at and enlarged while proliferation ®nally stopped at subcon¯uent densities. This was in contrast with cultures of primary foreskin ®broblasts (PFF cells) that grew steadily to con¯uence and adopted the typical morphology of normal ®broblasts. In order to compare the expression of hp19 ARF in both cell types, immunoprecipitation plus Western blotting were performed on extracts prepared from equal numbers of HS-27 and PFF cells ( Figure  5b ). While the protein was detected in both cells, the intensity of the signal was signi®cantly higher in HS-27 cells than in PFF cells. These data suggested that the hp19 ARF protein tends to accumulate in cells that acquire a senescent phenotype. In this respect, hp19 ARF may be similar to p16 INK4a which has been reported to be present at elevated levels in primary ®broblasts at senescence (Hara et al., 1996; Alcorta et al., 1996) , as well as in uroepithelial cell cultures undergoing senescence (Rezniko et al., 1996) .
Discussion
The data presented in this paper on the human p19 ARF (hp19 ARF ) protein are in general agreement with results already reported for the murine p19 ARF protein . Both murine and human molecular species are found in the nucleus and appear to be expressed at low levels in normal cells. In contrast, we have detected abundant amounts of the human protein in some cultured tumor cells (HeLa cells, Meg-01 cells). In view of the inhibitory cell cycle activity of p19 ARF , this ®nding suggests that an inactive form of the protein is present in these tumor cells. Alternatively, it may re¯ect a defect in the biochemical pathway in which hp19 ARF is involved. Presently, no partner of hp19 ARF has been identi®ed. It is, therefore, interesting that Quelle et al. recently mentioned the association of mp19 ARF with several proteins by virtue of their speci®c coimmunoprecipitation from metabolically labeled murine cells infected with a retrovirus encoding the wild type p19 ARF protein (Quelle et al., 1997) . Importantly, these proteins were not detected when a construct lacking the N-terminal moiety only encoded by exon 1b was utilized to transfect recipient cells.
The other interesting result presented in this work is the absence of the protein in cells that abundantly express the b transcript (Duro et al., 1995) . Noticeably, in all the experiments presented here, the same cell lines were used to analyse in parallel RNA and protein expression. Several hypotheses may be formulated to explain this discrepancy. Either the protein is immediately degraded by proteolytic activity immediately following its translation. In this respect, a p27 kip1 proteasome-mediated degradative activity has been recently reported in extracts of colon carcinoma tissues that contained no p27 protein or only low levels (Loda et al., 1997) . In contrast, carcinomas expressing high p27 protein levels appeared to be devoid of this proteolytic activity. While a similar situation may exist for hp19 ARF , we do not presently favor it. First, to be active, the putative protease activity should be immediately available. Although this condition is likely to occur in cell extracts where all cell components have been disrupted during the extraction procedure, it appears most unlikely that protease activity is at work based on the results provided by IIF studies involving immediate ®xation and therefore stabilization of the cell structure (see Table 1 ). Furthermore, by analogy with the p27 kip1 data (Loda et al., 1997) , some residual hp19 ARF could be expected to be present in the cells exhibiting the proteolytic activity. Finally, it is striking that no lysine residue that is required for ubiquitination, the ®rst step of degradation, is present in the primary structure of hp19 ARF . However, we cannot rule out the possibility that a protease activity is present in those tumor cells in which the b transcript and hp19 ARF expression are not correlated.
A second possibility is that the hp19 ARF mRNA is actually not translated in the protein-negative cell line analysed in the present study. In this respect, a particular structure of the 5' part of the native b transcript synthesized in these cell lines might prevent its ecient translation. However, all our eorts to isolate more 5' transcripts were unsuccessful. Other groups have also failed to isolate some longer transcripts (Stone et al., 1995) . These data indirectly support the idea of an anomalous 5' mRNA structure that inhibits its translation. Interestingly, a sequence analysis of the 5' genomic sequence surrounding exon 1b has shown the presence of a CpG-rich region and a GT-rich region suggestive of a GT box promoter element (Mao et al., 1995) . In spite of numerous CpG dinucleotides, this region has not been reported to be methylated (Swaord et al., 1997) .
Another point to consider is the presence of a speci®c factor inhibiting the translation of the b transcript in tumor cells that express it at high levels. In view of the cell cycle inhibitory function of hp19 ARF , this hypothesis is attractive as it is conceivable that such a putative inhibitor would have been selected by cancer cells in order to relieve them from growth inhibition. One evident prediction of this model is that hp19 ARF is involved in tumorigenic processes. However, the most recent data on this point do not suggest that this is the case (see Quelle et al., 1997 and references herein) .
Finally, a completely dierent possibility is that the hp19 ARF protein present in some human tumor cell lines is not recognized by the antibodies we used. The recent suggestion that a truncated protein, comprised of the only exon 1b-encoded moiety, might be expressed in tumor cells is plausible as such a truncated species might not contain the epitopes reacting with our antibodies (Quelle et al., 1997) . We do not have currently any indication of the epitopic speci®city of the serum used throughout this study.
In conclusion, similar to the uncoupling of hp19 ARF RNA and protein expression described herein, it has been reported that, in mouse skin carcinoma cell lines and human hepatocarcinomas (cell lines and tumors), the presence of the a transcript was not accompanied by p16 INK4a protein expression (Linardopoulos et al., 1995; Hui et al., 1996) . Since no mutation was apparently detected, these results as well as ours suggest that p16
INK4a expression and hp19 ARF expression may be inactivated by posttranscriptional regulation rather than by genomic alterations. Moreover, the fact that the hp19 ARF protein is frequently absent in tumor cells that express its mRNA, suggests that the protein might play a still unknown function in tumorigenic processes despite the absence of any point mutation in the coding sequence. The presence of increased protein levels in certain tumor cells grown in culture (for example HeLa cells) does not contradict this notion as, in these cells other partners, (or eectors) of hp19 ARF may be impaired or missing.
were added to the supernatants recovered by centrifugation at 12 000 r.p.m. for 1 min. Incubation was continued overnight at 48C, and protein A sepharose was added for 45 min at 48C. The immune complexes were processed as previously reported (Soulard et al., 1993) and half of the reaction mixtures were run on 16.5% polyacrylamide gel using Tricine buer (SchaÈ gger et al., 1987) . The proteins were then transferred to nitrocellulose membrane which were probed for 4 h with 1/500 dilution of anti-hp19 ARF or anti-p16 INK4 rabbit sera, then incubated with 1/2000 dilution of anti-rabbit Ig coupled to horseradish peroxidase (Amersham) for 20 min at 48C. Finally, bound antibody was detected by chemiluminescence (ECL, Amersham) according to the manufacturer's instructions.
Indirect immuno¯uorescence microscopy
Cells were ®xed with 3% paraformaldehyde in PBS pH 7.4 for 10 min at room temperature, washed in PBS, permeabilized by 0.2% Triton X-100 in PBS and washed three more times with PBS. The slides were incubated with 1/200 dilution of anti-hp19 ARF polyclonal rabbit sera or 1/50 dilution of anti-HA mouse monoclonal antibody (Boehringer Mannheim). Finally, the slides were washed three times in PBS and incubated for 20 min at room temperature with 1/200 dilution of¯uorescein-conjugated, donkey and sheep respectively, anti-rabbit or anti-mouse Ig (Amersham).
Transfection procedures
Because of the presence of a SacI site inside the hp19 ARF insert, clone 13 DNA was digested at the unique EcoRI cloning site of the vector, and the resulting fragment was subcloned into bluescript KS plasmid. Upon ampli®cation, the hp19 ARF insert of the recombinant subclone DNA was recovered by SacI digestion and integrated in frame with hemagglutinin (HA) into DEB vector (Boulukoz et al., 1989 , a gift of Dr J Ghysdael, Institut Curie, Orsay, France).
Hela and Cos cells were transfected by using the standard calcium phosphate technique (Sambrook et al., 1989) . Hela cells were also transfected using the DMRIE-C reagent according to the manufacturer's instructions (Gibco-BRL).
